Urology
Erectile Dysfunction
Cardiovascular risk marker; lifestyle + PDE5 inhibitors → second-line.
Source: BSSM 2018; NICE CKS
Step 1 of ~2
info
Workup
ED in men <60 = predictor of CV events within 3 years.
History: morning erections (preserved suggests psychogenic > organic), comorbidities, drugs (thiazides, beta-blockers, SSRIs, antipsychotics, finasteride, opioids, alcohol).
Examination: BP, BMI, secondary sexual characteristics, genital exam (Peyronie's), femoral pulses, PR.
Bloods: 9 AM testosterone × 2 if low, prolactin, LH/FSH, glucose / HbA1c, lipids, U&E, LFTs, TFTs, PSA.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Sildenafil · PDE5 Inhibitor — Pulmonary Arterial Hypertension
- Sildenafil (CTD-Associated PAH / Raynaud's) · Phosphodiesterase-5 (PDE5) Inhibitor
- Vardenafil · PDE5 Inhibitor — Erectile Dysfunction
- Avanafil · PDE5 Inhibitor — Erectile Dysfunction
- Avanafil · Phosphodiesterase Type 5 (PDE5) Inhibitor (Erectile Dysfunction)
- Phenytoin / Fosphenytoin · Antiepileptic — Status Epilepticus (Second-Line)
Decision support only. Always apply local guidelines and clinical judgement.